Insider trading

Period: 120 months Stock: DTIL Plan: Scheduled (10b5-1) × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

29 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

29 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

29 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

29 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
29 decisions over 120 months Remove this filter
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
29 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

29 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
18 Feb 2026
Amoroso Michael President and CEO
Sold on a plan
$78.95K 20,559 at 3.84
7.8%
Planned (10b5-1)
18 Feb 2026
Kelly John Alexander Chief Financial Officer
Sold on a plan
$31.29K 8,149 at 3.84
6.1%
Planned (10b5-1)
18 Feb 2026
SMITH J. JEFFERSON Chief Research Officer
Sold on a plan
$18.91K 4,925 at 3.84
3.9%
Planned (10b5-1)
18 Feb 2026
Scimeca Dario General Counsel and Secretary
Sold on a plan
$18.91K 4,925 at 3.84
8.0%
Planned (10b5-1)
22 Jan 2026
Amoroso Michael President and CEO
Sold on a plan
$145.11K 34,799 at 4.17
15.1%
Planned (10b5-1)
21 Jan 2026
Kelly John Alexander Chief Financial Officer
Sold on a plan
$61.31K 15,213 at 4.03
12.5%
Planned (10b5-1)
21 Jan 2026
SMITH J. JEFFERSON Chief Research Officer
Sold on a plan
$41.11K 10,200 at 4.03
8.5%
Planned (10b5-1)
21 Jan 2026
Scimeca Dario General Counsel and Secretary
Sold on a plan
$35.68K 8,854 at 4.03
16.5%
Planned (10b5-1)
3 Nov 2025
Amoroso Michael President and CEO
Sold on a plan
$22.12K 3,409 at 6.49
2.9%
Planned (10b5-1)
3 Nov 2025
Kelly John Alexander Chief Financial Officer
Sold on a plan
$8.46K 1,303 at 6.49
1.7%
Planned (10b5-1)
3 Nov 2025
Scimeca Dario General Counsel and Secretary
Sold on a plan
$4.32K 665 at 6.49
2.3%
Planned (10b5-1)
3 Jul 2025
Kelly John Alexander Chief Financial Officer
Sold on a plan
$63.16K 14,827 at 4.26
16.8%
Planned (10b5-1)
24 Mar 2025
Amoroso Michael President and CEO
Sold on a plan
$5.36K 964 at 5.56
0.9%
Planned (10b5-1)
4 Mar 2025
Scimeca Dario General Counsel and Secretary
Sold on a plan
$1.34K 272 at 4.91
1.1%
Planned (10b5-1)
4 Mar 2025
SMITH J. JEFFERSON Chief Research Officer
Sold on a plan
$756.14 154 at 4.91
0.2%
Planned (10b5-1)
22 Jan 2025
SMITH J. JEFFERSON Chief Research Officer
Sold on a plan
$49.27K 10,287 at 4.79
10.5%
Planned (10b5-1)
22 Jan 2025
Scimeca Dario General Counsel and Secretary
Sold on a plan
$42.77K 8,928 at 4.79
26.8%
Planned (10b5-1)
21 Jan 2025
Amoroso Michael President and CEO
Sold on a plan
$172.03K 36,838 at 4.67
25.6%
Planned (10b5-1)
4 Nov 2024
Scimeca Dario General Counsel and Secretary
Sold on a plan
$4.82K 588 at 8.19
6.9%
Planned (10b5-1)
10 Jun 2024
Scimeca Dario General Counsel and Secretary
Sold on a plan
$1.10K 93 at 11.79
1.4%
Planned (10b5-1)
2 May 2024
Scimeca Dario General Counsel and Secretary
Sold on a plan
$2.81K 272 at 10.32
4.6%
Planned (10b5-1)
22 Jan 2024
Amoroso Michael President and CEO
Sold on a plan
$49.46K 137,390 at 0.36
27.8%
Planned (10b5-1)
22 Jan 2024
List Alan Chief Medical Officer
Sold on a plan
$7.75K 21,526 at 0.36
18.5%
Planned (10b5-1)
22 Jan 2024
Scimeca Dario General Counsel and Secretary
Sold on a plan
$7.66K 21,287 at 0.36
12.4%
Planned (10b5-1)
3 Nov 2023
Amoroso Michael President and CEO
Sold on a plan
$50.01K 125,025 at 0.40
35.5%
Planned (10b5-1)
3 Nov 2023
Scimeca Dario General Counsel and Secretary
Sold on a plan
$6.41K 16,023 at 0.40
12.4%
Planned (10b5-1)
8 Jun 2023
Scimeca Dario General Counsel and Secretary
Sold on a plan
$10.02K 13,361 at 0.75
16.3%
Planned (10b5-1)
27 Apr 2023
List Alan Chief Medical Officer
Sold on a plan
$6.14K 7,771 at 0.79
12.1%
Planned (10b5-1)
22 Mar 2023
Amoroso Michael President and CEO
Sold on a plan
$38.54K 46,999 at 0.82
40.6%
Planned (10b5-1)
Showing 1–29 of 29.